EW Edwards Lifesciences Corporation Common Stock
$91,21
Precio · Ago 18, 2026
Fundamentales a fecha de Ago 4, 2026
Rango 52S
$72–$96
79% of range
Calificación del Analista
BUY
40 analysts
Precio Objetivo
$101
+11% upside
P/E (TTM)
56.6
ROE
10.6%
Margen de Beneficio Neto
17.7%
Acerca de Edwards Lifesciences Corporation Common Stock Descripción general de la empresa de Wikipedia
Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in tissue heart valves and transcatheter technologies for the treatment of structural heart disease. The company has manufacturing facilities at the Irvine headquarters, as well as in Draper, Utah; Costa Rica; Singapore; and Limerick, Ireland. The company is also constructing a manufacturing plant in Moncada, near Valencia, Spain, with a €150 million investment. Production is scheduled to begin in 2027.
Leer más
Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in tissue heart valves and transcatheter technologies for the treatment of structural heart disease. The company has manufacturing facilities at the Irvine headquarters, as well as in Draper, Utah; Costa Rica; Singapore; and Limerick, Ireland. The company is also constructing a manufacturing plant in Moncada, near Valencia, Spain, with a €150 million investment. Production is scheduled to begin in 2027.
History
Edwards Lifesciences was originally founded by electrical engineer Miles "Lowell" Edwards in 1958, a graduate of Oregon State University. Edwards invented the first medically proven and adopted artificial heart valve. Dr. Albert Starr, a surgeon at the Oregon Health and Sciences University, is credited as the first to successfully implant the Starr-Edwards mitral valve in a patient in 1960. As a result of the successful heart implant, Edwards established manufacturing in Santa Ana, California the same year to continue his research in pulmonary devices.
Edwards' valves are still in operation today. An early patient lived a record 48 years with the implant before requiring a replacement.
Edwards was acquired by Baxter in 1985. It was spun off from Baxter in 2000.
In 2017, Edwards completed the acquisition of Valtech Cardio for $340 million. Also in 2017, Edwards acquired Harpoon Medical of Baltimore, Maryland for $100 million. Harpoon, founded in 2013, developed a minimally invasive heart surgery product for mitral valve repair to treat degenerative mitral regurgitation. At the time of the acquisition, the product was not available on any market.
On April 18, 2019, Edwards completed the acquisition of CAS Medical Systems of Branford, Connecticut for ~$100 million.
Edwards Sapien 3 and Sapien 3 Ultra Transcatheter Heart Valve systems were FDA-approved for the treatment of patients at low risk for death or major complications associated with open-heart surgery on August 16, 2019. These products are used to treat patients with severe aortic stenosis without utilizing open-heart surgery.
In 2020, Edwards co-sponsored the Virtual ISPOR-FDA Summit centered on patient preference information in medical device regulatory decisions.
In December 2021, the FDA approved the SAPIEN 3 transcatheter valve in combination with the Alterra adaptive prestent for the treatment of severe pulmonary regurgitation.
In February 2024, the FDA approved Edwards' EVOQUE tricuspid valve replacement system, the first transcatheter therapy approved in the United States for the treatment of tricuspid regurgitation. In May 2024, Edwards launched the SAPIEN 3 Ultra RESILIA valve in Europe.
In June 2024, the company received FDA approval for a new implant designed to manage heart failure issues, called the Cordella pulmonary artery sensor.
In July 2024, Edwards made agreements with Affluent Medical for an equity stake, IP licensing and an exclusive option to acquire its Kephalios subsidiary. The same month, Edwards announced it would acquire Innovalve Bio Medical for approximately $300 million, and JenaValve Technology and Endotronix for $1.2 billion.
In August 2024, Edwards acquired JC Medical from Genesis MedTech, gaining its J-Valve transcatheter aortic valve replacement system for the treatment of aortic regurgitation.
In 2023, Edwards announced that its critical care business unit would be spun off into a separate entity. In June 2024 Edwards instead agreed to sell the unit to BD for $4.2 billion. The sale closed on September 3, 2024.
In May 2025, the FDA approved the SAPIEN 3 platform, including the SAPIEN 3, SAPIEN 3 Ultra, and SAPIEN 3 Ultra RESILIA valves, for the treatment of severe aortic stenosis in asymptomatic patients, marking the first FDA approval of TAVR therapy for this patient population.
In September 2025, Edwards completed the full acquisition of heart failure monitoring company Vectorious Medical Technologies.
In January 2026, the FDA approved the SAPIEN M3 mitral valve replacement system, the first transcatheter mitral valve replacement therapy using a transseptal approach to receive FDA approval for the treatment of mitral regurgitation.
Business segments
Prior to September 2024, its products were categorized into four areas: surgical valve technologies, transcatheter heart valves, transcatheter mitral and tricuspid therapies, and critical care. In September 2024, Edwards completed the sale of its Critical Care product group to BD. Since September 2024, its products are categorized into four areas: surgical valve technologies, transcatheter heart valves, transcatheter mitral and tricuspid therapies, and implantable heart failure management (IHFM).
Transcatheter Heart Valve
The company's SAPIEN family of transcatheter aortic heart valves is made of bovine pericardial tissue mounted within a balloon-expandable, cobalt-chromium frame and is deployed via catheter. Edwards introduced the transcatheter heart valve replacement procedure to U.S. patients unable to undergo open-heart surgery with FDA approval of the SAPIEN transcatheter valve in 2011. The indication was expanded in November 2012 to include patients at a high risk for death or serious complications associated with open-heart surgery. In 2021, the FDA cleared Edwards’ SAPIEN 3 transcatheter valve with the Alterra adaptive prestent for pulmonic heart valve replacement. In May 2024, Edwards launched the SAPIEN 3 Ultra RESILIA valve in Europe.
Transcatheter Mitral and Tricuspid Therapies
The Transcatheter Mitral and Tricuspid Therapies business segment develops transcatheter heart valve repair and replacement technologies to treat mitral and tricuspid valve diseases. In September 2022, the FDA approved Edwards' PASCAL Precision transcatheter valve repair system for the treatment of degenerative mitral regurgitation.
Surgical
The Surgical business segment involves the use of Edwards' RESILIA tissue technology, developed to help limit valve calcification. Edwards estimates that more than 450,000 patients around the world have either undergone SAVR or TAVR with an Edwards RESILIA valve.
Critical Care
Before its sale, the Critical Care business segment included pulmonary artery catheters, disposable pressure transducers and advanced hemodynamic monitoring systems. The portfolio also included a line of balloon catheter-based vascular products, surgical clips and inserts. In 2023, it was announced that the critical care business unit was to be spun off into its own entity, however in 2024 the critical care department was purchased by BD for $4.2 billion.
Organizational culture
Edwards Lifesciences Foundation
The Edwards Lifesciences Foundation launched in 2014 and supports programs designed to treat underserved people to reduce heart valve disease.
Since the initiative launched in 2014, Edwards and its foundation have contributed more than $100 million in financial and technology donations through "Every Heartbeat Matters" (EHM), reaching over 4 million underserved structural heart patients globally.
Fuente: Wikipedia (Inglés), CC BY-SA 4.0 · Ver en Wikipedia ↗
EW Instantánea de la Acción Precio, capitalización bursátil, P/E, BPA, ROE, deuda/capital, rango de 52 semanas
Precio
$91.21
Capitalización Bursátil
$60.20B
P/E (TTM)
56.6
BPA (TTM)
$1.83
Ingresos (TTM)
$6.07B
Rendimiento div.
—
ROE
10.6%
Deuda/Capital
0.1
Rango 52S
$72 – $96
EW Gráfico del Precio de la Acción OHLCV diario con indicadores técnicos — desplace, amplíe y personalice su vista
Configure
Rendimiento a 10 años Tendencias de ingresos, beneficio neto, márgenes y BPA
Ingresos y Beneficio Neto
$6.07B
2016-12-31
→
2025-12-31
BPA
$1.83
2016-12-31
→
2025-12-31
Flujo de caja libre
$1.33B
2016-12-31
→
2025-12-31
Márgenes
17.7%
2016-12-31
→
2025-12-31
Valoración Ratios P/E, P/S, P/B, EV/EBITDA: ¿está la acción cara o barata?
Métrica
Tendencia a 5 años
EW
Mediana de Pares
P/E (TTM)
56.6
26.3
P/S (TTM) (P/V (TTM))
9.9
4.4
P/B (P/C)
5.8
5.3
EV / EBITDA
39.8
—
Price / FCF (Precio / FCF)
45.1
—
Rentabilidad Márgenes brutos, operativos y netos; ROE, ROA, ROIC
Métrica
Tendencia a 5 años
EW
Mediana de Pares
Gross Margin (Margen Bruto)
78.0%
63.1%
Operating Margin (Margen Operativo)
20.8%
—
Net Profit Margin (Margen de Beneficio Neto)
17.7%
15.6%
ROA
8.0%
7.6%
ROE
10.6%
15.0%
ROIC
9.6%
—
Salud financiera Deuda, liquidez, solvencia — solidez del balance general
Métrica
Tendencia a 5 años
EW
Mediana de Pares
Debt / Equity (Deuda / Patrimonio)
0.1
—
Current Ratio (Ratio corriente)
3.7
1.7
Quick Ratio (Ratio Rápido)
2.7
—
Crecimiento Crecimiento de ingresos, BPA y beneficio neto: interanual, CAGR a 3 años, CAGR a 5 años
Métrica
Tendencia a 5 años
EW
Mediana de Pares
Revenue YoY (Ingresos interanuales)
11.6%
—
Revenue CAGR 3Y (Ingresos CAGR 3A)
10.8%
—
Revenue CAGR 5Y (Ingresos CAGR 5A)
6.7%
—
EPS YoY (EPS interanual)
-73.7%
—
Net Income YoY (Beneficio Neto interanual)
-74.3%
—
Eficiencia de capital Rotación de activos, rotación de inventario, rotación de cuentas por cobrar
Métrica
Tendencia a 5 años
EW
Mediana de Pares
EW Consenso de analistas Opiniones de analistas alcistas y bajistas, precio objetivo a 12 meses, potencial alcista
COMPRA
40 analistas
- Compra fuerte 13 32,5%
- Compra 17 42,5%
- Mantener 10 25,0%
- Venta 0 0,0%
- Venta fuerte 0 0,0%
Precio objetivo a 12 meses
26 analistas · 2026-08-19
Mediana
$101.50
Ahora
$91.21
Mín
$84.00
Máx
$110.00
Objetivo mediano
$101.50
+11,3%
Objetivo medio
$100.96
+10,7%
Historial de Ganancias EPS real vs estimado, sorpresa %, tasa de aciertos, próxima fecha de resultados
Sorpresa Media
0.02%
| Período | EPS Actual | EPS est. | Sorpresa |
|---|---|---|---|
| 30 de junio de 2026 | $0.78 | $0.76 | 0.02% |
| 31 de marzo de 2026 | $0.78 | $0.75 | 0.03% |
| 31 de diciembre de 2025 | $0.58 | $0.64 | -0.06% |
| 30 de septiembre de 2025 | $0.67 | $0.61 | 0.06% |
| 30 de junio de 2025 | $0.67 | $0.64 | 0.03% |
| 31 de marzo de 2025 | $0.64 | $0.61 | 0.03% |
Comparación de pares (subindustria GICS) Métricas clave frente a competidores del sector
| Ticker | Capitalización Bursátil | P/E | Ingresos interanuales | Margen Neto | ROE | Margen Bruto |
|---|---|---|---|---|---|---|
| EW | $49.50B | 46.6 | 11.6% | 17.7% | 10.6% | 78.0% |
| ABT | $250.18B | 33.7 | 5.7% | 14.7% | 13.1% | — |
| ISRG | $201.11B | 72.0 | 20.5% | 28.4% | 16.7% | 66.0% |
| SYK | $134.44B | 41.8 | 11.2% | 12.9% | 15.1% | 64.0% |
| BSX | — | 49.1 | 19.9% | 14.4% | 12.6% | 69.0% |
| BDX | — | 25.3 | 8.2% | 7.7% | 6.5% | — |
| IDXX | $53.93B | 51.7 | 10.4% | 24.6% | 69.2% | 61.8% |
| DXCM | $25.54B | 31.8 | 15.6% | 17.9% | 31.4% | 60.1% |
| GEHC | — | 18.0 | 4.8% | 10.1% | 22.1% | 40.0% |
| RMD | $28.11B | 18.7 | 9.8% | 26.9% | 23.6% | 61.1% |
| ZBH | $28.66B | 25.3 | 7.2% | 8.6% | 5.6% | — |
Fundamentales Completos Todas las métricas por año — estado de resultados, balance general, flujo de caja
Estado de resultados 17
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.07B | $5.44B | $5.01B | $4.46B | $5.23B | $4.39B | $4.35B | $3.72B | $3.44B | $2.96B | $2.49B | $2.32B | |
| Cost of Revenue | $1.33B | $1.12B | $978M | $724M | $1.25B | $1.08B | $1.11B | $939M | $875M | $797M | $617M | $626M | |
| Gross Profit | $4.73B | $4.32B | $4.03B | $3.74B | $3.98B | $3.31B | $3.23B | $2.78B | $2.56B | $2.17B | $1.88B | $1.70B | |
| R&D Expense | $1.08B | $1.05B | $963M | $844M | $903M | $761M | $753M | $622M | $553M | $442M | $383M | $346M | |
| SG&A Expense | $2.09B | $1.79B | $1.58B | $1.36B | $1.49B | $1.23B | $1.24B | $1.09B | $991M | $905M | $851M | $858M | |
| Operating Income | $1.26B | $1.38B | $1.31B | $1.50B | $1.69B | $898M | $1.15B | $748M | $1.09B | $751M | · | · | |
| Interest Expense | · | · | $18M | $19M | $18M | $16M | $21M | $30M | $23M | $19M | $17M | $17M | |
| Interest Income | $169M | $120M | $67M | $36M | $17M | $23M | $32M | $32M | $20M | $11M | $8M | $6M | |
| Other Non-op | $7M | $69M | $14M | $5M | $13M | $12M | $8M | $4M | $-1M | $-5M | $-4M | $-8M | |
| Pretax Income | $1.27B | $1.55B | $1.37B | $1.52B | $1.70B | $917M | $1.17B | $761M | $1.03B | $738M | $622M | $1.14B | |
| Income Tax | $217M | $152M | $152M | $196M | $199M | $93M | $120M | $39M | $451M | $168M | $128M | $333M | |
| Net Income | $1.07B | $4.17B | $1.40B | $1.52B | $1.50B | · | · | · | · | · | · | · | |
| EPS (Basic) | $1.84 | $6.98 | $2.31 | $2.46 | $2.41 | $1.32 | $1.68 | $1.15 | $2.77 | $2.67 | $2.30 | $3.81 | |
| EPS (Diluted) | $1.83 | $6.97 | $2.30 | $2.44 | $2.38 | $1.30 | $1.64 | $1.13 | $2.70 | $2.61 | $2.25 | $3.74 | |
| Shares (Basic) | 584,800,000 | 597,700,000 | 606,700,000 | 619,000,000 | 623,300,000 | 622,600,000 | 624,800,000 | 627,600,000 | 210,900,000 | 213,000,000 | 215,500,000 | 213,000,000 | |
| Shares (Diluted) | 585,800,000 | 599,300,000 | 609,400,000 | 624,200,000 | 631,200,000 | 631,900,000 | 636,700,000 | 640,900,000 | 215,900,000 | 217,800,000 | 220,300,000 | 217,000,000 | |
| EBITDA | $1.42B | $1.53B | $1.68B | $1.89B | $1.83B | $1.00B | $1.24B | $826M | $82M | $71M | $66M | $69M |
Balance general 29
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.94B | $3.05B | $1.13B | $769M | $863M | $1.18B | $1.18B | $714M | $818M | $930M | $718M | $654M | |
| Short-term Investments | $1.29B | $931M | $500M | $446M | $604M | $219M | $338M | $242M | $519M | $341M | $506M | $785M | |
| Receivables | $660M | $609M | $772M | $643M | $582M | $515M | $544M | $457M | $439M | $366M | $315M | $288M | |
| Inventory | $1.13B | $1.09B | $904M | $876M | $727M | $802M | $641M | $607M | $555M | $397M | $340M | $297M | |
| Prepaid Expense | $135M | $121M | $129M | $110M | $85M | $75M | $59M | $54M | $61M | $46M | $45M | $49M | |
| Other Current Assets | $339M | $348M | $225M | $196M | $237M | $208M | $168M | $132M | $117M | $112M | $66M | $122M | |
| Current Assets | $6.74B | $6.29B | $4.04B | $3.10B | $3.18B | $3.09B | $2.98B | $2.29B | $2.55B | $2.24B | $2.05B | $2.23B | |
| PP&E (Net) | $1.81B | $1.69B | $1.59B | $1.63B | $1.55B | $1.40B | $1.06B | $868M | $680M | $580M | $482M | $443M | |
| PP&E (Gross) | $2.66B | $2.48B | $2.29B | $2.38B | $2.20B | $1.99B | $1.57B | $1.32B | $1.09B | $961M | $854M | $808M | |
| Accum. Depreciation | $850M | $794M | $699M | $750M | $655M | $598M | $512M | $455M | $412M | $381M | $372M | $365M | |
| Goodwill | $1.77B | $1.78B | $1.15B | $1.06B | $1.17B | $1.17B | $1.17B | $1.11B | $1.13B | $626M | $628M | $376M | |
| Intangibles | $1.13B | $1.18B | $399M | $285M | $324M | $331M | $336M | $343M | $468M | $205M | $205M | $23M | |
| Other Non-current Assets | $730M | $722M | $463M | $299M | $111M | $120M | $102M | $34M | $109M | $123M | $132M | $49M | |
| Total Assets | $13.70B | $13.06B | $9.36B | $8.29B | $8.50B | $7.24B | $6.49B | $5.32B | $5.67B | $4.51B | $4.06B | $3.52B | |
| Accounts Payable | $228M | $197M | $187M | $202M | $204M | $196M | $180M | $134M | $117M | $97M | $64M | $58M | |
| Current Liabilities | $1.81B | $1.51B | $1.20B | $1.02B | $1.03B | $894M | $902M | $877M | $1.42B | $532M | $476M | $426M | |
| Capital Leases | $83M | $79M | $65M | $70M | $69M | $73M | $59M | · | · | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | $37M | · | · | · | · | · | |
| Other Non-current Liabilities | $362M | $373M | $251M | $218M | $267M | $252M | $203M | $150M | $147M | $115M | $285M | $113M | |
| Total Liabilities | $3.36B | $2.99B | $2.64B | $2.49B | $2.67B | $2.66B | · | · | · | · | · | · | |
| Long-term Debt | · | · | · | · | · | · | · | $594M | $1.04B | $822M | · | · | |
| Total Debt | $598M | $598M | $597M | $596M | $596M | $595M | $594M | $594M | $1.04B | $822M | $600M | $598M | |
| Common Stock | $659M | $655M | $650M | $646M | $642M | $636M | $218M | $215M | $212M | $243M | $239M | $129M | |
| Retained Earnings | $14.24B | $13.17B | $8.99B | $7.59B | $6.07B | $4.57B | $3.74B | $2.69B | $1.96B | $3.91B | $3.34B | $2.84B | |
| Treasury Stock | $7.09B | $6.19B | $5.02B | $4.14B | $2.42B | $1.90B | $1.28B | $1.02B | $252M | $2.50B | $1.84B | $1.56B | |
| AOCI | $-238M | $-244M | $-243M | $-255M | $-158M | $-161M | $-156M | $-138M | $-133M | $-198M | $-183M | $-101M | |
| Stockholders' Equity | $10.34B | $10.00B | $6.65B | $5.81B | $5.84B | $4.57B | $4.15B | $3.14B | $2.96B | $2.62B | $2.50B | $2.19B | |
| Liabilities + Equity | $13.70B | $13.06B | $9.36B | $8.29B | $8.50B | $7.24B | $6.49B | $5.32B | $5.67B | $4.51B | $4.06B | $3.52B | |
| Shares Outstanding | 580,700,000 | 654,800,000 | 650,500,000 | 646,300,000 | 642,000,000 | 636,400,000 | 218,100,000 | 207,700,000 | 209,700,000 | 211,600,000 | 215,400,000 | 107,800,000 |
Flujo de Efectivo 18
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $157M | $155M | $145M | $140M | $135M | $107M | $89M | $77M | $82M | $71M | $66M | $69M | |
| Stock-based Comp | $158M | $162M | $139M | $127M | $109M | $93M | $81M | $71M | $62M | $57M | $50M | $48M | |
| Deferred Tax | $-66M | $-163M | $-242M | $-262M | $-44M | $-52M | $10M | $-21M | $27M | $-24M | $-16M | $-67M | |
| Amort. of Intangibles | $8M | $6M | $2M | $2M | $8M | $5M | $5M | $2M | $8M | $8M | $7M | $8M | |
| Restructuring | $13M | $33M | · | · | · | · | · | · | · | · | $0 | $0 | |
| Other Non-cash | $273M | $-3.79B | $-529M | · | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $1.60B | $542M | $896M | $1.22B | $1.73B | $1.05B | $1.18B | $927M | $1.00B | $704M | $550M | $1.02B | |
| CapEx | $260M | $252M | $253M | $245M | $326M | $407M | $254M | $239M | $168M | $176M | $103M | $83M | |
| Investing Cash Flow | $-713M | $2.31B | $174M | $252M | $-1.72B | $-531M | $-596M | $77M | $-647M | $-212M | $-316M | · | |
| Debt Issued | · | · | $0 | $0 | $5M | $16M | $19M | $688M | $995M | $254M | $31M | $226M | |
| Net Debt Issued | · | · | $0 | $0 | $5M | $16M | $19M | $688M | $995M | $254M | $31M | $226M | |
| Stock Repurchased | $893M | $1.16B | $880M | $1.73B | $513M | $625M | $263M | $796M | $763M | $662M | $280M | $301M | |
| Net Stock Activity | $-893M | $-1.16B | $-880M | $-1.73B | $-513M | $-625M | $-263M | $-796M | $-763M | $-662M | $-280M | $-301M | |
| Financing Cash Flow | $-957M | $-983M | $-711M | $-1.58B | $-356M | $-487M | $-116M | $-1.10B | $-473M | $-268M | $-159M | · | |
| Net Change in Cash | $-119M | $1.91B | $375M | $-95M | $-333M | $16M | $468M | $-104M | $-112M | $212M | $65M | $233M | |
| Taxes Paid | $490M | $1.20B | $470M | · | · | · | · | · | · | · | · | $275M | |
| Free Cash Flow | $1.33B | $290M | $643M | $974M | $1.41B | $647M | $925M | $688M | $833M | $528M | $447M | $939M | |
| Levered FCF | · | · | $627M | $957M | $1.39B | $633M | $906M | $660M | $820M | $513M | $433M | $927M |
Rentabilidad 8
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 78.0% | 79.5% | 77.0% | 79.9% | 76.1% | 75.4% | 74.4% | 74.8% | 74.5% | 73.1% | 75.2% | 73.1% | |
| Operating Margin | 20.8% | 25.4% | 25.6% | 32.5% | 32.3% | 20.5% | 26.4% | 20.1% | · | · | · | · | |
| Net Margin | 17.7% | 76.8% | 23.4% | · | · | · | · | · | · | · | · | · | |
| Pretax Margin | 21.0% | 28.5% | 26.6% | 32.8% | 32.5% | 20.9% | 26.8% | 20.4% | 30.1% | 24.9% | 25.0% | 49.2% | |
| EBITDA Margin | 23.4% | 28.2% | 28.0% | 35.1% | 34.9% | 22.9% | 28.4% | 22.2% | 2.4% | 2.4% | 2.6% | 2.9% | |
| ROA | 8.0% | 37.2% | 15.9% | · | · | · | · | · | · | · | · | · | |
| ROE | 10.6% | 50.1% | 22.5% | · | · | · | · | · | · | · | · | · | |
| ROIC | 9.6% | 11.7% | 18.5% | 23.5% | 23.2% | 15.6% | 21.7% | 19.0% | · | · | · | · |
Liquidez y Solvencia 5
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.7 | 4.2 | 3.4 | 3.0 | 3.1 | 3.5 | 3.3 | 2.6 | 1.8 | 4.2 | 4.3 | 5.3 | |
| Quick Ratio | 2.7 | 3.0 | 2.0 | 1.8 | 2.0 | 2.1 | 2.3 | 1.6 | 1.3 | 3.1 | 3.2 | 4.0 | |
| Debt / Equity | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | 0.4 | 0.3 | 0.2 | 0.3 | |
| LT Debt / Equity | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | 0.1 | 0.3 | 0.2 | 0.3 | |
| Interest Coverage | · | · | 87.2 | 91.1 | 91.9 | 56.8 | 55.4 | 25.0 | · | · | · | · |
Eficiencia 3
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.5 | 0.5 | 0.7 | 0.6 | 0.7 | 0.6 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | |
| Inventory Turnover | 1.2 | 1.1 | 1.4 | 1.3 | 1.6 | 1.5 | 1.8 | 1.6 | 1.8 | 2.2 | 1.9 | 2.1 | |
| Receivables Turnover | 9.6 | 7.9 | 8.5 | 8.8 | 9.5 | 8.3 | 8.7 | 8.3 | 8.7 | 8.7 | 8.3 | 7.9 |
Tasas de Crecimiento 8
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 11.6% | 8.6% | 12.2% | -14.7% | 19.3% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 10.8% | 1.3% | 4.5% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 6.7% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | -73.7% | 203.0% | -5.7% | 2.5% | 83.1% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | -9.1% | 43.1% | 20.9% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | 7.1% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | -74.3% | 197.7% | -7.8% | 1.2% | · | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | -11.0% | 40.6% | · | · | · | · | · | · | · | · | · | · |
Valoración (TTM) 14
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $6.07B | $5.44B | $5.01B | $4.46B | $5.23B | $4.39B | $4.35B | $3.72B | $3.44B | $2.96B | $2.49B | $2.32B | |
| Net Income TTM | $1.07B | $4.17B | $1.40B | $1.52B | $1.50B | $235M | $235M | $235M | $235M | $235M | $235M | $235M | |
| Market Cap | $49.50B | $43.57B | $45.83B | $45.39B | $80.85B | $56.95B | $16.26B | $10.60B | $7.88B | $6.61B | $5.67B | $2.29B | |
| Enterprise Value | $45.88B | $40.20B | $44.79B | $44.77B | $79.98B | $56.15B | $15.34B | $10.24B | $7.58B | $6.16B | $5.05B | $1.45B | |
| P/E | 46.6 | 10.6 | 33.2 | 30.6 | 54.4 | 70.2 | 47.4 | 45.2 | 13.9 | 12.0 | 11.7 | 5.7 | |
| P/S | 8.2 | 8.0 | 9.1 | 10.2 | 15.5 | 13.0 | 3.7 | 2.8 | 2.3 | 2.2 | 2.3 | 1.0 | |
| P/B | 4.8 | 4.4 | 6.9 | 7.8 | 13.9 | 12.5 | 3.9 | 3.4 | 2.7 | 2.5 | 2.3 | 1.0 | |
| P / Tangible Book | 6.7 | 6.2 | 9.0 | 10.2 | 18.6 | 18.6 | · | · | · | · | · | · | |
| P / Cash Flow | 31.0 | 80.4 | 51.2 | 37.3 | 46.7 | 54.0 | 13.8 | 11.4 | 7.9 | 9.4 | 10.3 | 2.2 | |
| P / FCF | 37.1 | 150.3 | 71.3 | 46.6 | 57.5 | 88.0 | 17.6 | 15.4 | 9.5 | 12.5 | 12.7 | 2.4 | |
| EV / EBITDA | 32.3 | 26.2 | 26.7 | 23.7 | 43.8 | 55.9 | 12.4 | 12.4 | 92.5 | 86.5 | 76.7 | 21.1 | |
| EV / FCF | 34.4 | 138.7 | 69.7 | 46.0 | 56.9 | 86.7 | 16.6 | 14.9 | 9.1 | 11.7 | 11.3 | 1.5 | |
| EV / Revenue | 7.6 | 7.4 | 8.9 | 10.0 | 15.3 | 12.8 | 3.5 | 2.8 | 2.2 | 2.1 | 2.0 | 0.6 | |
| Earnings Yield | 2.1% | 9.4% | 3.0% | 3.3% | 1.8% | 1.4% | 2.1% | 2.2% | 7.2% | 8.4% | 8.6% | 17.6% |
Estado de resultados 16
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.74B | $1.65B | $1.57B | $1.55B | $1.53B | $1.41B | $1.39B | $1.35B | $1.37B | $1.33B | $1.01B | $1.24B | $1.28B | $1.22B | $430M | $1.32B | |
| Cost of Revenue | $392M | $363M | $343M | $345M | $344M | $302M | $292M | $263M | $276M | $287M | $141M | $251M | $257M | $330M | $-99M | $254M | |
| Gross Profit | $1.35B | $1.29B | $1.23B | $1.21B | $1.19B | $1.11B | $1.09B | $1.09B | $1.09B | $1.04B | $870M | $993M | $1.03B | $992M | $529M | $1.07B | |
| R&D Expense | $279M | $263M | $268M | $281M | $276M | $255M | $271M | $253M | $272M | $257M | $215M | $243M | $244M | $261M | $131M | $234M | |
| SG&A Expense | $561M | $522M | $603M | $515M | $502M | $466M | $492M | $421M | $448M | $428M | $354M | $382M | $410M | $436M | $201M | $377M | |
| Operating Income | $513M | $478M | $151M | $307M | $411M | $395M | $313M | $351M | $366M | $349M | $291M | $366M | $264M | $388M | $198M | $402M | |
| Interest Income | $30M | $34M | · | · | $37M | $36M | · | · | · | · | · | · | · | · | · | · | |
| Other Non-op | $17M | $72M | $3M | $3M | $-1M | $3M | $33M | $28M | $2M | $6M | $3M | $7M | $2M | $2M | $6M | $-2M | |
| Pretax Income | $520M | $459M | $90M | $348M | $400M | $434M | $390M | $403M | $384M | $371M | $311M | $388M | $275M | $399M | $211M | $407M | |
| Income Tax | $278M | $78M | $26M | $56M | $64M | $70M | $45M | $41M | $20M | $46M | $21M | $53M | $21M | $58M | $11M | $64M | |
| Net Income | $242M | $381M | $91M | $291M | $333M | $358M | $386M | $3.07B | $366M | $352M | $370M | $385M | $307M | $340M | $398M | $344M | |
| EPS (Basic) | $0.42 | $0.66 | $0.16 | $0.50 | $0.57 | $0.61 | $0.65 | $5.14 | $0.61 | $0.58 | $0.61 | $0.63 | $0.51 | $0.56 | $0.66 | $0.55 | |
| EPS (Diluted) | $0.42 | $0.66 | $0.16 | $0.50 | $0.56 | $0.61 | $0.65 | $5.13 | $0.61 | $0.58 | $0.61 | $0.63 | $0.50 | $0.56 | $0.65 | $0.55 | |
| Shares (Basic) | 576,400,000 | 579,200,000 | -1,173,800,000 | 584,700,000 | 587,000,000 | 586,900,000 | -1,203,200,000 | 597,200,000 | 602,100,000 | 601,600,000 | -1,214,700,000 | 607,000,000 | 606,900,000 | 607,500,000 | -1,243,800,000 | 619,800,000 | |
| Shares (Diluted) | 577,600,000 | 580,700,000 | -1,175,600,000 | 585,700,000 | 587,900,000 | 587,800,000 | -1,207,200,000 | 598,100,000 | 604,300,000 | 604,100,000 | -1,221,300,000 | 609,500,000 | 610,300,000 | 610,900,000 | -1,256,400,000 | 624,500,000 | |
| EBITDA | $513M | $518M | · | $307M | $411M | $431M | · | $351M | $369M | $426M | · | $418M | $327M | $424M | · | $402M |
Balance general 27
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.91B | $2.45B | $2.94B | $2.69B | $3.27B | $3.14B | $3.05B | $3.68B | $1.64B | $1.22B | · | $1.41B | $1.04B | $872M | · | $1.25B | |
| Short-term Investments | $1.35B | $1.23B | $1.29B | $1.16B | $789M | $758M | $931M | $770M | $345M | $473M | · | $454M | $467M | $382M | · | $491M | |
| Receivables | $770M | $776M | $660M | $693M | $697M | $669M | $609M | $716M | $778M | $818M | · | $740M | $754M | $718M | · | $618M | |
| Inventory | $1.13B | $1.12B | $1.13B | $1.14B | $1.14B | $1.11B | $1.09B | $1.10B | $1.02B | $1.21B | · | $1.03B | $980M | $914M | · | $758M | |
| Prepaid Expense | $119M | $136M | $135M | $125M | $110M | $111M | $121M | $115M | $110M | $138M | · | $133M | $123M | $119M | · | $88M | |
| Other Current Assets | $360M | $330M | $339M | $323M | $314M | $304M | $348M | $231M | $252M | $251M | · | $236M | $217M | $190M | · | $268M | |
| Current Assets | $6.82B | $6.23B | $6.74B | $6.36B | $6.58B | $6.21B | $6.29B | $6.73B | $4.52B | $4.17B | · | $4.07B | $3.65B | $3.26B | · | $3.51B | |
| PP&E (Net) | $1.84B | $1.82B | $1.81B | $1.74B | $1.73B | $1.70B | $1.69B | $1.68B | $1.64B | $1.77B | · | $1.68B | $1.66B | $1.65B | · | $1.57B | |
| PP&E (Gross) | · | · | $2.66B | · | · | · | $2.48B | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $850M | · | · | · | $794M | · | · | · | · | · | · | · | · | · | |
| Goodwill | $1.95B | $1.82B | $1.77B | $1.77B | $1.78B | $1.78B | $1.78B | $1.61B | $1.15B | $1.25B | $1.15B | $1.30B | $1.30B | $1.31B | $1.06B | $1.16B | |
| Intangibles | $1.38B | $1.23B | $1.13B | $1.13B | $1.17B | $1.17B | $1.18B | $956M | $417M | $447M | · | $430M | $431M | $447M | · | $266M | |
| Other Non-current Assets | $616M | $739M | $730M | $785M | $743M | $743M | $722M | $684M | $790M | $768M | · | $447M | $412M | $294M | · | $316M | |
| Total Assets | $13.87B | $13.32B | $13.70B | $13.27B | $13.49B | $13.02B | $13.06B | $12.97B | $10.10B | $9.74B | · | $9.37B | $9.00B | $8.65B | · | $8.64B | |
| Accounts Payable | $210M | $181M | $228M | $165M | $162M | $172M | $197M | $173M | $186M | $212M | · | $191M | $193M | $181M | · | $155M | |
| Current Liabilities | $1.51B | $1.41B | $1.81B | $1.59B | $1.40B | $1.39B | $1.51B | $1.94B | $1.22B | $1.11B | · | $1.24B | $1.16B | $1.08B | · | $918M | |
| Capital Leases | $82M | $80M | $83M | $75M | $79M | $78M | $79M | $85M | $74M | $77M | · | $70M | $64M | $66M | · | $67M | |
| Other Non-current Liabilities | $382M | $351M | $362M | $363M | $379M | $358M | $373M | $323M | $257M | $266M | · | $240M | $243M | $260M | · | $221M | |
| Total Liabilities | $3.14B | $2.99B | $3.36B | $3.07B | $2.88B | $2.83B | $2.99B | $3.36B | $2.59B | $2.55B | · | $2.64B | $2.56B | $2.59B | · | $2.42B | |
| Total Debt | $599M | $598M | · | $598M | $598M | $598M | · | $598M | $597M | $597M | · | $597M | $597M | $596M | · | $596M | |
| Common Stock | $662M | $660M | $659M | $658M | $658M | $656M | $655M | $654M | $654M | $652M | · | $650M | $649M | $647M | · | $646M | |
| Retained Earnings | $14.86B | $14.62B | $14.24B | $14.15B | $13.86B | $13.53B | $13.17B | $12.78B | $9.71B | $9.34B | · | $8.62B | $8.24B | $7.93B | · | $7.19B | |
| Treasury Stock | $7.67B | $7.51B | $7.09B | $7.05B | $6.46B | $6.45B | $6.19B | $6.09B | $5.18B | $5.02B | · | $4.58B | $4.40B | $4.39B | · | $3.28B | |
| AOCI | $-215M | $-221M | $-238M | $-250M | $-264M | $-254M | $-244M | $-252M | $-220M | $-233M | · | $-250M | $-256M | $-255M | · | $-256M | |
| Stockholders' Equity | $10.62B | $10.33B | $10.34B | $10.21B | $10.55B | $10.13B | $10.00B | $9.55B | $7.44B | $7.12B | · | $6.66B | $6.38B | $5.98B | · | $6.22B | |
| Liabilities + Equity | $13.87B | $13.32B | $13.70B | $13.27B | $13.49B | $13.02B | $13.06B | $12.97B | $10.10B | $9.74B | · | $9.37B | $9.00B | $8.65B | · | $8.64B | |
| Shares Outstanding | 576,600,000 | 577,000,000 | 580,700,000 | 580,700,000 | 587,900,000 | 586,200,000 | 588,600,000 | 589,800,000 | 602,300,000 | 602,400,000 | 650,500,000 | 606,500,000 | 607,900,000 | 606,000,000 | 646,300,000 | 619,400,000 |
Flujo de Efectivo 13
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $43M | $41M | $43M | $39M | $38M | $37M | $43M | $34M | $40M | $38M | $37M | $37M | $36M | $35M | $35M | $35M | |
| Stock-based Comp | $42M | $45M | $39M | $41M | $38M | $40M | $32M | $42M | $44M | $45M | $30M | $33M | $37M | $39M | $28M | $30M | |
| Restructuring | · | · | $5M | $100.0K | · | · | $0 | $33M | · | · | · | $0 | · | · | · | · | |
| Other Non-cash | · | $-423M | · | · | · | $-154M | · | · | · | $-488M | · | · | · | · | · | · | |
| Operating Cash Flow | $652M | $44M | $451M | $574M | $290M | $280M | $-128M | $352M | $372M | $-54M | $137M | $412M | $34M | $314M | $283M | $310M | |
| CapEx | $67M | $65M | $97M | $58M | $49M | $56M | $50M | $52M | $85M | $65M | $88M | $55M | $48M | $62M | $69M | $60M | |
| Investing Cash Flow | $-193M | $-93M | $-198M | $-428M | $-172M | $85M | $-577M | $2.70B | $125M | $63M | $14M | $89M | $70M | $500.0K | $95M | $-202M | |
| Debt Issued | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | |
| Stock Repurchased | $153M | $422M | $41M | $589M | $6M | $259M | $100M | $901M | $158M | $200.0K | $448M | $174M | $8M | $249M | $866M | $100M | |
| Net Stock Activity | · | $-422M | · | · | · | $-259M | · | · | · | $-200.0K | · | · | · | $-249M | · | · | |
| Financing Cash Flow | $-300.0K | $-451M | $-11M | $-740M | $53M | $-258M | $29M | $-977M | $-97M | $62M | $-413M | $-143M | $52M | $-207M | $-838M | $-70M | |
| Net Change in Cash | $462M | $-492M | $245M | $-595M | $141M | $90M | $-625M | $2.03B | $429M | $81M | $-266M | $366M | $171M | $104M | $-479M | $49M | |
| Free Cash Flow | · | $-21M | · | · | · | $224M | · | · | · | $-119M | · | · | · | $253M | · | · |
Rentabilidad 8
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 77.5% | 78.0% | · | 77.8% | 77.5% | 78.6% | · | 80.6% | 79.4% | 75.9% | · | 76.3% | 77.6% | 77.4% | · | 80.8% | |
| Operating Margin | 29.5% | 29.0% | · | 19.8% | 26.8% | 28.0% | · | 25.9% | 26.6% | 24.2% | · | 28.2% | 21.4% | 26.6% | · | 30.5% | |
| Net Margin | 13.9% | 23.1% | · | 18.7% | 21.8% | 25.3% | · | 226.7% | 26.4% | 22.0% | · | 26.0% | 20.1% | · | · | · | |
| Pretax Margin | 29.9% | 27.8% | · | 22.4% | 26.1% | 30.7% | · | 29.7% | 27.9% | 25.6% | · | 29.7% | 22.1% | 27.3% | · | 30.9% | |
| EBITDA Margin | 29.5% | 31.4% | · | 19.8% | 26.8% | 30.5% | · | 25.9% | 26.6% | 26.7% | · | 28.2% | 21.4% | 29.0% | · | 30.5% | |
| ROA | 1.8% | 2.9% | · | 2.2% | 2.8% | 3.1% | · | 27.5% | 3.8% | 3.8% | · | 4.3% | 3.5% | · | · | · | |
| ROE | 2.3% | 3.7% | · | 2.9% | 3.7% | 4.2% | · | 37.9% | 5.3% | 5.4% | · | 6.0% | 5.0% | · | · | · | |
| ROIC | 2.1% | 3.6% | · | 2.4% | 3.1% | 3.1% | · | 3.1% | 4.3% | 4.3% | · | 5.0% | 4.2% | 5.1% | · | 5.0% |
Liquidez y Solvencia 4
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.5 | 4.4 | · | 4.0 | 4.7 | 4.5 | · | 3.5 | 3.7 | 3.8 | · | 3.3 | 3.2 | 3.0 | · | 3.8 | |
| Quick Ratio | 3.3 | 3.2 | · | 2.9 | 3.4 | 3.3 | · | 2.7 | 2.3 | 2.3 | · | 2.1 | 2.0 | 1.8 | · | 2.6 | |
| Debt / Equity | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| LT Debt / Equity | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 |
Eficiencia 3
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | |
| Inventory Turnover | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.3 | · | 0.2 | 0.3 | 0.4 | · | 0.4 | 0.4 | 0.4 | · | 0.3 | |
| Receivables Turnover | 2.4 | 2.3 | · | 2.2 | 2.1 | 1.9 | · | 1.9 | 1.8 | 2.1 | · | 2.2 | 2.2 | 2.2 | · | 2.2 |
Valoración (TTM) 14
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $6.47B | $6.15B | · | $5.88B | $5.69B | $5.52B | · | $5.32B | $5.21B | $5.12B | · | $5.06B | $5.19B | $5.26B | · | $5.34B | |
| Net Income TTM | $1.25B | $1.36B | · | $1.37B | $4.15B | $4.18B | · | $4.16B | $1.47B | $1.41B | · | $1.38B | $1.40B | · | · | · | |
| Market Cap | $52.16B | $46.21B | · | $45.16B | $45.98B | $42.49B | · | $38.92B | $55.63B | $57.57B | · | $42.02B | $57.34B | $50.13B | · | $51.18B | |
| Enterprise Value | $48.51B | $43.13B | · | $41.92B | $42.52B | $39.19B | · | $35.07B | $54.24B | $56.46B | · | $40.75B | $56.43B | $49.48B | · | $50.04B | |
| P/E | 42.3 | 34.4 | · | 33.5 | 11.3 | 10.4 | · | 9.5 | 38.0 | 41.2 | · | 30.9 | 41.7 | 35.2 | · | 35.5 | |
| P/S | 8.1 | 7.5 | · | 7.7 | 8.1 | 7.7 | · | 7.3 | 10.7 | 11.2 | · | 8.3 | 11.0 | 9.5 | · | 9.6 | |
| P/B | 4.9 | 4.5 | · | 4.4 | 4.4 | 4.2 | · | 4.1 | 7.5 | 8.1 | · | 6.3 | 9.0 | 8.4 | · | 8.2 | |
| P / Tangible Book | 7.2 | 6.3 | · | 6.2 | 6.1 | 5.9 | · | 5.6 | 9.5 | 10.6 | · | 8.5 | 12.3 | 11.9 | · | 10.7 | |
| P / Cash Flow | · | 1054.9 | · | · | · | 151.5 | · | · | · | -1076.0 | · | · | · | 159.6 | · | · | |
| P / FCF | · | -2189.9 | · | · | · | 189.3 | · | · | · | -484.6 | · | · | · | 198.5 | · | · | |
| EV / EBITDA | 94.5 | 83.2 | · | 136.5 | 103.4 | 90.8 | · | 100.0 | 147.0 | 132.5 | · | 97.4 | 172.5 | 116.8 | · | 124.4 | |
| EV / FCF | · | -2044.2 | · | · | · | 174.6 | · | · | · | -475.3 | · | · | · | 195.9 | · | · | |
| EV / Revenue | 7.5 | 7.0 | · | 7.1 | 7.5 | 7.1 | · | 6.6 | 10.4 | 11.0 | · | 8.0 | 10.9 | 9.4 | · | 9.4 | |
| Earnings Yield | 2.4% | 2.9% | · | 3.0% | 8.9% | 9.7% | · | 10.5% | 2.6% | 2.4% | · | 3.2% | 2.4% | 2.8% | · | 2.8% |
Estados Financieros Estado de resultados, balance general, flujo de caja — anual, últimos 5 años
Estado de resultados
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Ingresos | $6.07B | $5.44B | $5.01B | $4.46B | $5.23B |
| Margen Bruto % | 78.0% | 79.5% | 77.0% | 79.9% | 76.1% |
| Margen Operativo % | 20.8% | 25.4% | 25.6% | 32.5% | 32.3% |
| Beneficio neto | $1.07B | $4.17B | $1.40B | $1.52B | $1.50B |
| EPS Diluido | $1.83 | $6.97 | $2.30 | $2.44 | $2.38 |
Balance general
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Deuda / Patrimonio | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
| Ratio corriente | 3.7 | 4.2 | 3.4 | 3.0 | 3.1 |
| Ratio Rápido | 2.7 | 3.0 | 2.0 | 1.8 | 2.0 |
Flujo de Efectivo
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Flujo de caja libre | $1.33B | $290M | $643M | $974M | $1.41B |
Mis Métricas Tu lista de seguimiento personal — filas seleccionadas de Fundamentales Completos
📊
Elige las métricas que te importan — haz clic en el ➕ junto a cualquier fila en Fundamentales Completos arriba.
Tu selección se guarda y te sigue en todos los tickers.
Propietarios institucionales (13F) 1 442 declarantes · $30.2B total · A fecha de 30 de junio de 2026
Instituciones que informan tener esta acción en su Formulario 13F trimestral de la SEC. Solo posiciones largas; un solo presentador puede aparecer dos veces para tramos de opciones separados. Las patas de put/call de compensación grandes suelen reflejar la creación de mercado o el inventario cubierto, no la convicción direccional.
Actividad institucional — Q2 2026 vs trimestre anterior
| Nuevas posiciones | Posiciones cerradas | Aumentado | Disminuido | Cambio neto de acciones |
|---|---|---|---|---|
| 152 (+6 vs trimestre anterior) | 97 (-10 vs trimestre anterior) | 459 (+11 vs trimestre anterior) | 452 (+4 vs trimestre anterior) | +26.4M |
Comparado con Q1 2026. Las presentaciones del Formulario 13F de la SEC vencen dentro de los 45 días posteriores al final del trimestre, más un pequeño margen para los presentadores tardíos; los trimestres que aún se encuentran dentro de esa ventana se omiten en favor del par más reciente completamente reportado.
| Institución | Valor | Acciones | % de 13F rastreadas | Tipo |
|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $3 402 739 018 | 37 615 952 | 11,25% | Acciones |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $2 389 175 425 | 26 411 402 | 7,90% | Acciones |
| STATE STREET CORP | $2 381 082 692 | 26 321 940 | 7,87% | Acciones |
| WELLINGTON MANAGEMENT GROUP LLP | $1 430 999 585 | 15 819 142 | 4,73% | Acciones |
| GEODE CAPITAL MANAGEMENT, LLC | $1 219 437 867 | 13 541 730 | 4,03% | Acciones |
| DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main | $1 135 640 991 | 12 554 068 | 3,75% | Acciones |
| Ninety One UK Ltd | $1 116 050 276 | 12 337 502 | 3,69% | Acciones |
| Aristotle Capital Management, LLC | $783 906 442 | 8 665 712 | 2,59% | Acciones |
| NORGES BANK | $757 492 410 | 8 373 783 | 2,50% | Acciones |
| ALLIANCEBERNSTEIN L.P. | $693 526 113 | 8 660 416 | 2,29% | Acciones |
| FMR LLC | $607 177 379 | 6 712 109 | 2,01% | Acciones |
| Artisan Partners Limited Partnership | $599 361 052 | 6 625 703 | 1,98% | Acciones |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $513 572 538 | 5 677 344 | 1,70% | Acciones |
| WELLCOME TRUST LTD (THE) as trustee of the WELLCOME TRUST | $434 208 000 | 4 800 000 | 1,44% | Acciones |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $334 052 859 | 3 692 824 | 1,10% | Acciones |
| MILLENNIUM MANAGEMENT LLC | $324 280 556 | 3 584 795 | 1,07% | Acciones |
| CITADEL ADVISORS LLC | $308 338 066 | 3 408 557 | 1,02% | Acciones |
| PRIMECAP MANAGEMENT CO/CA/ | $308 314 004 | 3 408 291 | 1,02% | Acciones |
| DIMENSIONAL FUND ADVISORS LP | $298 865 427 | 3 303 843 | 0,99% | Acciones |
| BROWN ADVISORY INC | $295 062 880 | 3 261 805 | 0,98% | Acciones |
| VANGUARD FIDUCIARY TRUST CO | $292 399 738 | 3 232 365 | 0,97% | Acciones |
| Holocene Advisors, LP | $283 979 721 | 3 139 285 | 0,94% | Acciones |
| NEUBERGER BERMAN GROUP LLC | $255 069 412 | 2 818 763 | 0,84% | Acciones |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $250 776 107 | 2 772 232 | 0,83% | Acciones |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $238 277 000 | 2 634 054 | 0,79% | Acciones |
| Mirova US LLC | $229 802 865 | 2 540 381 | 0,76% | Acciones |
| BANK OF AMERICA CORP /DE/ | $170 884 489 | 1 889 061 | 0,56% | Acciones |
| BlackRock, Inc. | $168 018 323 | 1 857 377 | 0,56% | Acciones |
| Assenagon Asset Management S.A. | $163 997 286 | 1 812 926 | 0,54% | Acciones |
| Point72 Asset Management, L.P. | $160 486 895 | 1 774 120 | 0,53% | Acciones |
| RAYMOND JAMES FINANCIAL INC | $152 806 000 | 1 689 211 | 0,51% | Acciones |
| Swiss National Bank | $147 097 006 | 1 626 100 | 0,49% | Acciones |
| Woodline Partners LP | $141 123 209 | 1 560 062 | 0,47% | Acciones |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $140 351 128 | 1 551 434 | 0,46% | Acciones |
| TWO SIGMA INVESTMENTS, LP | $137 670 984 | 1 521 899 | 0,46% | Acciones |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $131 472 173 | 1 453 357 | 0,43% | Acciones |
| Mitsubishi UFJ Asset Management Co., Ltd. | $126 120 870 | 1 394 217 | 0,42% | Acciones |
| Legal & General Group Plc | $121 108 845 | 1 338 811 | 0,40% | Acciones |
| ROYAL BANK OF CANADA | $119 193 000 | 1 317 637 | 0,39% | Acciones |
| Sumitomo Mitsui Trust Group, Inc. | $113 885 341 | 1 258 958 | 0,38% | Acciones |
| Quantinno Capital Management LP | $113 292 795 | 1 252 407 | 0,37% | Acciones |
| Vanguard Global Advisers, LLC | $112 247 472 | 1 240 852 | 0,37% | Acciones |
| VANGUARD GROUP INC | $107 656 172 | 1 262 829 | 0,36% | Acciones |
| SEB Asset Management AB | $106 981 085 | 1 182 636 | 0,35% | Acciones |
| Liontrust Investment Partners LLP | $106 083 480 | 1 244 381 | 0,35% | Acciones |
| VANGUARD ASSET MANAGEMENT, Ltd | $100 522 409 | 1 111 236 | 0,33% | Acciones |
| Polar Capital Holdings Plc | $99 945 636 | 1 104 860 | 0,33% | Acciones |
| RHUMBLINE ADVISERS | $99 213 696 | 1 096 770 | 0,33% | Acciones |
| BNP PARIBAS FINANCIAL MARKETS | $92 822 996 | 1 026 122 | 0,31% | Acciones |
| PARNASSUS INVESTMENTS, LLC | $91 873 890 | 1 015 630 | 0,30% | Acciones |
| Bank of New York Mellon Corp | $91 654 072 | 1 013 200 | 0,30% | Acciones |
| National Pension Service | $90 349 187 | 998 775 | 0,30% | Acciones |
| California Public Employees Retirement System | $89 091 250 | 984 869 | 0,29% | Acciones |
| Caisse de depot et placement du Quebec | $87 523 397 | 967 537 | 0,29% | Acciones |
| ABN AMRO Bank N.V. | $83 573 385 | 924 314 | 0,28% | Acciones |
| GOLDMAN SACHS GROUP INC | $82 454 109 | 911 498 | 0,27% | Acciones |
| Empower Advisory Group, LLC | $80 384 543 | 888 620 | 0,27% | Acciones |
| Meridiem Capital Partners LP | $77 697 994 | 858 921 | 0,26% | Acciones |
| Man Group plc | $76 372 212 | 844 265 | 0,25% | Acciones |
| ORBIMED ADVISORS LLC | $75 525 054 | 834 900 | 0,25% | Acciones |
| Alyeska Investment Group, L.P. | $73 531 316 | 812 860 | 0,24% | Acciones |
| Nantahala Capital Management, LLC | $72 368 000 | 800 000 | 0,24% | Opción de venta |
| CANADA PENSION PLAN INVESTMENT BOARD | $72 254 020 | 798 740 | 0,24% | Acciones |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $69 805 736 | 871 700 | 0,23% | Acciones |
| ENVESTNET ASSET MANAGEMENT INC | $66 940 606 | 740 002 | 0,22% | Acciones |
| Bellevue Group AG | $66 871 108 | 739 234 | 0,22% | Acciones |
| Birch Hill Investment Advisors LLC | $66 522 203 | 735 377 | 0,22% | Acciones |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $64 772 074 | 716 030 | 0,21% | Acciones |
| TD Asset Management Inc | $61 560 472 | 680 527 | 0,20% | Acciones |
| PRINCIPAL FINANCIAL GROUP INC | $61 491 904 | 679 769 | 0,20% | Acciones |
| UBS Group AG | $60 908 889 | 673 324 | 0,20% | Acciones |
| Candriam S.C.A. | $59 988 129 | 663 784 | 0,20% | Acciones |
| VIRGINIA RETIREMENT SYSTEMS ET Al | $57 604 363 | 675 711 | 0,19% | Acciones |
| Integral Health Asset Management, LLC | $56 537 500 | 625 000 | 0,19% | Acciones |
| Ninety One North America, Inc. | $55 768 413 | 616 498 | 0,18% | Acciones |
| Robeco Institutional Asset Management B.V. | $55 270 246 | 610 991 | 0,18% | Acciones |
| Seilern Investment Management Ltd | $54 296 896 | 600 231 | 0,18% | Acciones |
| Nan Shan Life Insurance Co., Ltd. | $49 953 912 | 552 221 | 0,17% | Acciones |
| PFA Pension, Forsikringsaktieselskab | $49 175 025 | 543 611 | 0,16% | Acciones |
| BARCLAYS PLC | $49 135 520 | 543 174 | 0,16% | Acciones |
| Triodos Investment Management BV | $44 629 165 | 493 358 | 0,15% | Acciones |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $44 266 149 | 489 345 | 0,15% | Acciones |
| Mitsubishi UFJ Trust & Banking Corp | $43 182 890 | 477 370 | 0,14% | Acciones |
| APG Asset Management N.V. | $42 840 046 | 541 444 | 0,14% | Acciones |
| United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund | $42 480 287 | 469 603 | 0,14% | Acciones |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $42 097 461 | 465 371 | 0,14% | Acciones |
| AVIVA PLC | $41 577 497 | 459 623 | 0,14% | Acciones |
| Balyasny Asset Management L.P. | $41 248 584 | 455 987 | 0,14% | Acciones |
| Korea Investment CORP | $40 486 097 | 447 558 | 0,13% | Acciones |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $39 585 296 | 437 600 | 0,13% | Opción de compra |
| NORDEA INVESTMENT MANAGEMENT AB | $37 761 927 | 418 322 | 0,12% | Acciones |
| STOREBRAND ASSET MANAGEMENT AS | $37 671 343 | 416 442 | 0,12% | Acciones |
| Qube Research & Technologies Ltd | $37 490 061 | 414 438 | 0,12% | Acciones |
| OFI INVEST ASSET MANAGEMENT | $36 480 086 | 458 427 | 0,12% | Acciones |
| Fisher Funds Management LTD | $35 971 057 | 397 646 | 0,12% | Acciones |
| LPL Financial LLC | $34 985 891 | 386 755 | 0,12% | Acciones |
| ABN AMRO INVESTMENT SOLUTIONS | $33 668 217 | 372 189 | 0,11% | Acciones |
| AMERIPRISE FINANCIAL INC | $32 517 021 | 359 463 | 0,11% | Acciones |
| BLAIR WILLIAM & CO/IL | $32 206 687 | 356 032 | 0,11% | Acciones |
| Champlain Investment Partners, LLC | $31 357 054 | 346 640 | 0,10% | Acciones |
Informantes de la empresa 48 insiders · 18 directivos · 8 consejeros
| Insider | Rol | Última actividad | Acciones en propiedad | Compras 12m | Ventas 12m | Neto 12m |
|---|---|---|---|---|---|---|
| Bernard J Zovighian | CEO | 27 de julio de 2026 S | 8 916 | 0 | 8 | $-6 996 971 |
| Theodora Mistras | CVP, Chief Financial Officer | 9 de julio de 2026 A | 99 920 | 0 | 0 | $0 |
| Thomas M Abate | CVP, CFO | 14 de mayo de 2013 A | 43 047 | 0 | 0 | $0 |
| Wayne Markowitz | CVP, JAPAC | 30 de julio de 2026 S | 21 534 | 0 | 4 | $-928 942 |
| Annette Bruls | CVP, EMEACLA | 11 de julio de 2026 F | 20 628 | 0 | 0 | $0 |
| Andrew M. Dahl | SVP, Corporate Controller | 29 de mayo de 2026 S | 15 334 | 0 | 1 | $-48 893 |
| Carlyn D Solomon | CVP, Critical Care & Vascular | 28 de octubre de 2014 M | 31 154 | 0 | 0 | $0 |
| Christine Z Mccauley | CVP, Human Resources | 13 de mayo de 2013 F | 4 035 | 0 | 0 | $0 |
| Paul C Redmond | CVP, Global Operations | 13 de mayo de 2013 S | 12 534 | 0 | 0 | $0 |
| Bruce P Garren | CVP, Public Affairs/Special Co | 13 de mayo de 2013 F | 56 071 | 0 | 0 | $0 |
| John H Kehl JR | CVP, Strategy & Corp Dev | 7 de mayo de 2013 F | 101 767 | 0 | 0 | $0 |
| Robert C Reindl | CVP, H.R. and Communications | 27 de julio de 2012 M | 1 124 | 0 | 0 | $0 |
| Aimee S Weisner | CVP, General Counsel | 9 de mayo de 2012 A | 1 675 | 0 | 0 | $0 |
| Corinne H Nevinny | CVP & Pres., Global Ops | 13 de mayo de 2010 A | 16 687 | 0 | 0 | $0 |
| Anita Bessler | CVP | 31 de agosto de 2007 S | 29 410 | 0 | 0 | $0 |
| John Alexander Martin | CVP, North America | 10 de mayo de 2007 A | 15 300 | 0 | 0 | $0 |
| Stuart L Foster | CVP, Critical Care / Vascular | 10 de mayo de 2007 A | 24 604 | 0 | 0 | $0 |
| Randel William Woodgrift | Corp VP, Manufacturing Ops | 4 de agosto de 2005 M | 3 349 | 0 | 0 | $0 |
| John T Cardis | Consejero | 10 de agosto de 2016 S | 91 458 | 0 | 0 | $0 |
| Barbara J Mcneil | Consejero | 4 de febrero de 2016 S | 46 454 | 0 | 0 | $0 |
| Robert Alexander Ingram | Consejero | 15 de mayo de 2015 A | 32 367 | 0 | 0 | $0 |
| Michael R Bowlin | Consejero | 14 de noviembre de 2014 M | 81 751 | 0 | 0 | $0 |
| David E I Pyott | Consejero | 9 de mayo de 2014 A | 53 582 | 0 | 0 | $0 |
| NEAL PHILIP M | Consejero | 12 de agosto de 2008 M | 27 333 | 0 | 0 | $0 |
| Vernon R Loucks JR | Consejero | 9 de mayo de 2008 A | 24 133 | 0 | 0 | $0 |
| Daniel J. Lippis | — | 11 de agosto de 2026 M | 40 034 | 0 | 12 | $-817 452 |
| Donald E Bobo JR | — | 27 de mayo de 2026 S | 98 611 | 0 | 12 | $-11 153 294 |
| Daveen Chopra | — | 22 de mayo de 2026 S | 44 324 | 0 | 3 | $-500 535 |
| Scott B. Ullem | — | 11 de mayo de 2026 M | 46 740 | 0 | 7 | $-3 875 008 |
| Leslie C. Davis | — | 8 de mayo de 2026 A | 9 834 | 0 | 0 | $0 |
| Ramona Sequeira | — | 8 de mayo de 2026 A | 6 779 | 0 | 0 | $0 |
| David T Feinberg | — | 8 de mayo de 2026 A | 9 087 | 0 | 0 | $0 |
| Kieran Gallahue | — | 8 de mayo de 2026 A | 4 315 | 0 | 0 | $0 |
| Nicholas J Valeriani | — | 8 de mayo de 2026 A | 84 423 | 0 | 0 | $0 |
| Heisz Leslie Stone | — | 8 de mayo de 2026 A | 34 199 | 0 | 1 | $-218 117 |
| Steven R Loranger | — | 8 de mayo de 2026 A | 8 997 | 0 | 0 | $0 |
| Paul A Laviolette | — | 8 de mayo de 2026 A | 17 552 | 0 | 0 | $0 |
| Larry L Wood | — | 18 de agosto de 2025 M | 206 900 | 0 | 0 | $0 |
| Catherine M. Szyman | — | 3 de septiembre de 2024 F | 81 287 | 0 | 0 | $0 |
| Jean-Luc M Lemercier | — | 7 de julio de 2024 F | 184 686 | 0 | 0 | $0 |
| Robert W.A. Sellers | — | 11 de mayo de 2024 F | 17 081 | 0 | 0 | $0 |
| Michael A Mussallem | — | 2 de mayo de 2024 M | 4 486 | 0 | 0 | $0 |
| Martha H. Marsh | — | 12 de mayo de 2023 A | 31 880 | 0 | 0 | $0 |
| Huimin Wang | — | 8 de julio de 2022 M | 99 381 | 0 | 0 | $0 |
| William J Link PHD | — | 8 de mayo de 2020 A | 11 349 | 0 | 0 | $0 |
| Wesley W Von Schack | — | 1 de agosto de 2019 S | 8 000 | 0 | 0 | $0 |
| Patrick B Verguet | — | 31 de mayo de 2017 M | 129 137 | 0 | 0 | $0 |
| Randall J Nelson | — | 30 de septiembre de 2003 A | — | 0 | 0 | $0 |
Informantes de las presentaciones SEC Form 3/4/5; neto = solo P/S de mercado abierto
Activistas y propietarios del %+ 5 1 tenencia
Inversores que presentaron el Anexo 13D de la SEC — propiedad beneficiosa superior al % 5 con la intención de influir en el emisor (participaciones activistas, campañas de la junta directiva, M&A). Cada fila muestra el estado conocido más reciente de la posición de ese declarante.
| Declarante | Presentado | Participación | Estado | Propósito | Presentación |
|---|---|---|---|---|---|
| Persona informante no revelada | 5 de abril de 2001 | — | Presentación inicial | Campaña de la junta directiva | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Propiedad de ETFs Mantenido por 180 ETFs
El peso refleja solo las tenencias directas de acciones (N-PORT); los fondos apalancados o basados en derivados pueden tener exposición adicional a swaps no mostrada.
| Fondo | Ponderación | Unidades | A fecha de | Fuente |
|---|---|---|---|---|
| IHI · iShares Trust | 4,29% | 1 607 851 SH | 8 de agosto de 2026 | Diario |
| GDOC · Goldman Sachs ETF Trust | 2,98% | 6 939 NS | 31 de mayo de 2026 | N-PORT |
| FMED · Fidelity Covington Trust | 2,11% | 10 000 NS | 31 de mayo de 2026 | N-PORT |
| ANEW · ProShares Trust | 2,02% | 1 801 NS | 31 de mayo de 2026 | N-PORT |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 1,83% | 2 435 NS | 30 de abril de 2026 | N-PORT |
| PJBF · PGIM ETF Trust | 1,75% | 2 374 NS | 29 de mayo de 2026 | N-PORT |
| HRTS · Tema ETF Trust | 1,75% | 10 488 NS | 31 de mayo de 2026 | N-PORT |
| RSPH · Invesco Exchange-Traded Fund Trust | 1,58% | 137 940 SH | 8 de agosto de 2026 | Diario |
| VOT · VANGUARD INDEX FUNDS | 1,14% | 4 411 246 SH | 8 de agosto de 2026 | Diario |
| ALTL · Pacer Funds Trust | 0,94% | 10 780 NS | 30 de abril de 2026 | N-PORT |
| CVAR · ETF Opportunities Trust | 0,93% | 4 325 NS | 30 de abril de 2026 | N-PORT |
| SDG · iShares Trust | 0,90% | 17 447 SH | 8 de agosto de 2026 | Diario |
| FFND · Northern Lights Fund Trust II | 0,88% | 10 459 NS | 31 de mayo de 2026 | N-PORT |
| IYH · iShares Trust | 0,83% | 341 366 SH | 8 de agosto de 2026 | Diario |
| BKDV · BNY Mellon ETF Trust II | 0,81% | 134 666 NS | 30 de abril de 2026 | N-PORT |
| NULV · Nushares ETF Trust | 0,79% | 197 378 NS | 30 de abril de 2026 | N-PORT |
| JOET · Virtus ETF Trust II | 0,79% | 22 410 NS | 30 de abril de 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0,78% | 267 514 NS | 30 de abril de 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0,77% | 1 733 147 SH | 8 de agosto de 2026 | Diario |
| NULC · Nushares ETF Trust | 0,75% | 5 090 NS | 30 de abril de 2026 | N-PORT |
| RXL · ProShares Trust | 0,73% | 6 052 NS | 31 de mayo de 2026 | N-PORT |
| CURE · Direxion Shares ETF Trust | 0,70% | 11 571 NS | 30 de abril de 2026 | N-PORT |
| IMCG · iShares Trust | 0,66% | 301 692 SH | 8 de agosto de 2026 | Diario |
| IXJ · iShares Trust | 0,65% | 302 050 SH | 8 de agosto de 2026 | Diario |
| TEC · Harbor ETF Trust | 0,61% | 491 NS | 30 de abril de 2026 | N-PORT |
| FWD · AB Active ETFs, Inc. | 0,56% | 187 544 NS | 31 de mayo de 2026 | N-PORT |
| HUSV · First Trust Exchange-Traded Fund III | 0,56% | 4 857 NS | 30 de abril de 2026 | N-PORT |
| BRNY · EA Series Trust | 0,54% | 35 555 NS | 30 de abril de 2026 | N-PORT |
| AVMC · AMERICAN CENTURY ETF TRUST | 0,53% | 24 654 NS | 31 de mayo de 2026 | N-PORT |
| SUSA · iShares Trust | 0,51% | 237 552 SH | 8 de agosto de 2026 | Diario |
| VO · VANGUARD INDEX FUNDS | 0,50% | 12 477 902 SH | 8 de agosto de 2026 | Diario |
| IWS · iShares Trust | 0,49% | 860 071 SH | 8 de agosto de 2026 | Diario |
| FXH · First Trust Exchange-Traded AlphaDE… | 0,42% | 44 305 NS | 30 de abril de 2026 | N-PORT |
| HELO · J.P. Morgan Exchange-Traded Fund Tr… | 0,40% | 193 493 NS | 30 de abril de 2026 | N-PORT |
| JOYT · J.P. Morgan Exchange-Traded Fund Tr… | 0,37% | 3 768 NS | 30 de abril de 2026 | N-PORT |
| IWR · iShares Trust | 0,36% | 2 320 860 SH | 8 de agosto de 2026 | Diario |
| IMCB · iShares Trust | 0,34% | 63 843 SH | 8 de agosto de 2026 | Diario |
| JGLO · J.P. Morgan Exchange-Traded Fund Tr… | 0,34% | 286 558 NS | 30 de abril de 2026 | N-PORT |
| EVUS · iShares Trust | 0,31% | 12 935 SH | 8 de agosto de 2026 | Diario |
| NBCR · Neuberger Berman ETF Trust | 0,30% | 30 404 NS | 31 de mayo de 2026 | N-PORT |
| OMFL · Invesco Exchange-Traded Self-Indexe… | 0,29% | 156 342 SH | 8 de agosto de 2026 | Diario |
| XOEF · iShares Trust | 0,28% | 720 SH | 8 de agosto de 2026 | Diario |
| ESUM · Strategy Shares | 0,27% | 5 033 NS | 30 de abril de 2026 | N-PORT |
| DFLV · Dimensional ETF Trust | 0,27% | 189 108 NS | 30 de abril de 2026 | N-PORT |
| WINN · Harbor ETF Trust | 0,24% | 31 226 NS | 30 de abril de 2026 | N-PORT |
| DEUS · DBX ETF Trust | 0,24% | 7 428 NS | 29 de mayo de 2026 | N-PORT |
| HEQQ · J.P. Morgan Exchange-Traded Fund Tr… | 0,23% | 887 NS | 30 de abril de 2026 | N-PORT |
| FFLG · FIDELITY COVINGTON TRUST | 0,22% | 15 544 NS | 30 de abril de 2026 | N-PORT |
| CAPE · DoubleLine ETF Trust | 0,22% | 7 122 NS | 31 de marzo de 2026 | N-PORT |
| GSEW · Goldman Sachs ETF Trust | 0,21% | 42 168 NS | 31 de mayo de 2026 | N-PORT |